Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction
Open Access
- 17 March 2004
- journal article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 43 (6) , 1019-1026
- https://doi.org/10.1016/j.jacc.2003.10.043
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Burden of Systolic and Diastolic Ventricular Dysfunction in the CommunityJAMA, 2003
- Plasma Natriuretic Peptides for Community Screening for Left Ventricular Hypertrophy and Systolic DysfunctionJAMA, 2002
- Plasma brain natriuretic peptide concentration: impact of age and genderJournal of the American College of Cardiology, 2002
- Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspneaJournal of the American College of Cardiology, 2002
- ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)Circulation, 2001
- Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure?European Heart Journal, 1998
- Biochemical detection of left-ventricular systolic dysfunctionThe Lancet, 1998
- Correspondence of left ventricular ejection fraction determinations from two-dimensional echocardiography, radionuclide angiography and contrast cineangiographyJournal of the American College of Cardiology, 1995
- Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure.Circulation, 1993
- Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection FractionsNew England Journal of Medicine, 1992